Our program seeks to clarify cellular and molecular mechanisms that lead to chronic asthma in order to identify novel, more effective therapies. We concentrate on immune mechanisms that underlie chronic airway inflammation with a clear focus on one immune tolerance molecule, the class I major histocompatibility complex protein human leukocyte antigen (HLA)-G, that we believe has an important role in modulating airway inflammation that is critical to chronic asthma. The key premise of our AADCRC proposal is that understanding the role of HLA-G will lead to new and better therapies to alleviate the suffering caused by asthma. To this end we propose three highly integrated and related projects: in Project 1, we will examine the presence and regulation of expression of HLA-G in asthmatic airways and in the airway epithelium, and relate presence to asthma severity and to the expression of regulating microRNA. We will examine the regulation of HLA-G expression by key Th2 cytokines such as IL-13 that are important to chronic asthma and relate expression back to airway cytokine concentrations in chronic asthma. In Project 2, we will exploit naturally occurring genetic variations in HLA-G and its LILRB receptors to understand how signaling through HLA-G and its receptors regulate the transition of CD4+ lymphocytes to the Th2 phenotype in mild/moderate asthma and to the Th17 phenotype in severe asthma. This project also will examine how genetic variation in the LILRB receptors modulate the effects of HLA-G on both T cell phenotype and on the SHP1 and SHP2 signaling pathways that modulate airway smooth muscle hypertrophy in chronic asthma. In Project 3, we will elucidate mechanisms that account for the higher risk of asthma among children of asthmatic mothers compared to children of non-asthmatic mothers. Using HLA-G as a model of the interactions of genotype and asthma status in mother and child, we will identify differentially expressed genes and the mechanisms for their differential expression in airway epithelium, CD4+ T cells and airway smooth muscle in subjects with chronic asthma. To complete these projects, each will interact with a robust Patient Recruitment and Data Analysis Core that will recruit 100 carefully phenotyped and genotyped asthmatic subjects and additional control subjects, and collect blood and airway biological specimens to be used in each project through a Lung Biological Specimens Core that will provide analytical and long-term storage. We believe that our current levels of productivity and collaboration combined with new, exciting and cutting-edge questions in this proposal will allow us to be successful in achieving our overall goal - identifying novel therapeutic targets for chronic asthma.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI095230-03
Application #
8503584
Study Section
Special Emphasis Panel (ZAI1-PA-I (M1))
Program Officer
Minnicozzi, Michael
Project Start
2011-07-25
Project End
2016-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
3
Fiscal Year
2013
Total Cost
$2,107,018
Indirect Cost
$769,072
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Stein, Michelle M; Thompson, Emma E; Schoettler, Nathan et al. (2018) A decade of research on the 17q12-21 asthma locus: Piecing together the puzzle. J Allergy Clin Immunol 142:749-764.e3
Hrusch, C L; Manns, S T; Bryazka, D et al. (2018) ICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s. Mucosal Immunol 11:61-70
Ober, Carole; Sperling, Anne I; von Mutius, Erika et al. (2017) Immune development and environment: lessons from Amish and Hutterite children. Curr Opin Immunol 48:51-60
White, Steven R; Nicodemus-Johnson, Jessie; Laxman, Bharathi et al. (2017) Elevated levels of soluble humanleukocyte antigen-G in the airways are a marker for a low-inflammatory endotype of asthma. J Allergy Clin Immunol 140:857-860
Press, Valerie G; Kelly, Colleen A; Kim, John J et al. (2017) Virtual Teach-To-Goalâ„¢ Adaptive Learning of Inhaler Technique for Inpatients with Asthma or COPD. J Allergy Clin Immunol Pract 5:1032-1039.e1
Krishack, Paulette A; Wang, Kanix; Rzhetsky, Andrey et al. (2017) Preexisting Type 2 Immune Activation Protects against the Development of Sepsis. Am J Respir Cell Mol Biol 57:628-630
Narayanamurthy, Vaishnavi; Sweetnam, John M; Denner, Darcy R et al. (2017) The metabolic footprint of the airway bacterial community in cystic fibrosis. Microbiome 5:67
Johnston, Henry Richard; Hu, Yi-Juan; Gao, Jingjing et al. (2017) Identifying tagging SNPs for African specific genetic variation from the African Diaspora Genome. Sci Rep 7:46398
Igartua, Catherine; Davenport, Emily R; Gilad, Yoav et al. (2017) Host genetic variation in mucosal immunity pathways influences the upper airway microbiome. Microbiome 5:16
Denner, Darcy R; Sangwan, Naseer; Becker, Julia B et al. (2016) Corticosteroid therapy and airflow obstruction influence the bronchial microbiome, which is distinct from that of bronchoalveolar lavage in asthmatic airways. J Allergy Clin Immunol 137:1398-1405.e3

Showing the most recent 10 out of 42 publications